

Ref. No: 2317
Date: 27/01/26
Subject: Chronic Lymphocytic Leukaemia (CLL)

REQUEST & RESPONSE

Q1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to?

Mersey and West Lancashire Teaching Hospitals	56
-----------------------------------------------	----

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:

- BR (bendamustine + rituximab) 0
- Brukinsa (zanubrutinib) 13
- Calquence (acalabrutinib) 44
- Calquence (acalabrutinib) + Gazyva (obinutuzumab) 0
- Calquence (acalabrutinib) + Venclyxto (venetoclax) <5
- Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab) 0
- FCR (fludarabine + cyclophosphamide + rituximab) 0
- Fludarabine Monotherapy 0
- Gazyva (obinutuzumab) + chlorambucil 0
- Imbruvica (ibrutinib) 10
- Venclyxto (venetoclax) 10
- Venclyxto (venetoclax) + Gazyva (obinutuzumab) 0
- Venclyxto (venetoclax) + rituximab 0
- Zydelig (idelalisib) + rituximab 0
- Imbruvica (Ibrutinib) +Venclyxto (venetoclax) 6
- Any other systemic anti-cancer therapy <5

Q3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:

- Brukinsa (zanubrutinib) - 0
- Calquence (acalabrutinib) - 0
- Imbruvica (ibrutinib) - 0
- Venclyxto (venetoclax) - <5
- Zydelig (idelalisib) + rituximab - 0
- Any other systemic anti-cancer therapy - 0

Q4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.

No